Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

Fig. 1

Gene aberration rates of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer. Patients tested for gene aberrations were classified as positive (activating mutations in exons 18-21), wild type, or unknown (findings inconclusive) for epidermal growth factor receptor (EGFR) gene mutations, and positive or negative for anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) gene fusions

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us